Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
This activity has been developed for community pharmacists whose practice calls upon them to assist and counsel patients who may benefit from using over-the-counter products as part of a self-directed healthcare regimen. The role of generic OTC and store-brand products are reviewed, as well as their economic benefits to the patient and pharmacy. Despite their perceived safety, OTC products can be associated with adverse effects. Important updates on the safe use of OTC products for peptic ulcer disease, allergies, birth control, and pain management are also discussed.
Upon completion of this activity, pharmacists will be able to:
Describe the evolving patient attitudes toward self-care and wellness, specifically in the context of OTC products
List important considerations for educating patients about the attributes of various OTC products and their efficacy
Identify the economic variables that influence patients’ use of OTC products, including brand, generic, and store-brand products
Describe the impact of healthcare reform initiatives on the role of physicians, pharmacists, and nurses who counsel patients on OTC products
Summarize the emergence of pharmacist-dispensed OTC products and the pharmacist’s role in effective counseling of patients seeking these items
James H. Wisner, BBA, MBA
President, Wisner Marketing Group, Inc.
Mary Lynn Moody, BSPharm
Director, Business Development
Drug Information Group
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed in this activity. Mr. Wisner has disclosed
that he has served as a consultant and/or speaker for the Perrigo Company. Ms. Moody
has disclosed that she has served as a consultant and/or speaker for the Perrigo Company.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
Release Date: 06-26-2014
Expiration Date: 06-26-2017
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-14-017-H01-P has been assigned to this knowledge-based, home-study activity (initial release date 06-26-14). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
This activity is supported by an educational grant from Perrigo.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.